News | November 13, 2014

ClearFlow Announces Positive Clinical Trial Results for the Reduction of Hospital Complications after Heart Surgery

Primary outcome was reduction of interventions for retained blood complications after heart surgery and prior to discharge

November 13, 2014 — ClearFlow Inc. announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial (PRO-ACT), a clinical study evaluating the use of PleuraFlow Active Clearance Technology System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clots in the early hours after heart surgery.

The PRO-ACT studied the efficacy of a protocol for actively clearing chest tubes of clotted blood to prevent retained blood complications. “Chest tube clogging is known to occur in over one-third of heart surgery patients in the early hours after heart surgery, and nearly one in five can have some form of retained blood complication that includes the need to perform subsequent invasive reinterventions to remove undrained blood or clot from inside the chest after heart surgery,” said Ed Boyle, M.D., the founder and chairman of ClearFlow. 

The primary outcome of this study was a reduction of interventions for retained blood complications after heart surgery and prior to discharge. The study results were presented at the Cardiovascular-Thoracic (CVT) Critical Care 2014 annual meeting, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, D.C.

The PRO-ACT results were presented by study principal investigator Theodor Fischlein, M.D., of Klinikum Nürnberg Heart Center. The results showed a statistically significant reduction of interventions for retained blood complications by 42 percent in the treatment group. In addition, the trial revealed a statistically significant reduction of postoperative atrial fibrillation (POAF). Patients treated with PleuraFlow System also had a statistically significant reduction in bleeding, suggesting that the Active Clearance Technology may help reduce the amount of bleeding after heart surgery.

“We are very pleased to have completed the first trial of its kind in this field that shows an immediate and significant reduction in the need for interventions for retained blood complications, as well as other common complications in patients recovering from heart surgery,” commented Fischlein. “We are always striving for ways to improve outcomes and this appears to be a promising technology that may achieve that goal.”

“Building on prior published studies showing that active clearance is superior to the currently used methods to remove shed blood from around the heart and lungs after heart surgery, this study shows a clear clinical benefit for patients that can also translate to a significant economic value for hospitals and payers,” commented Paul Molloy, President & CEO of ClearFlow. “Most hospitals are shouldering the burden of extensive cost increases due to lack of consistent protocols regarding blood evacuation post-cardiac surgery and the unacceptable failure with current available drains,” added Molloy. “We now have data from multiple sources that show approximately 20 percent of cardiac surgery patients require additional interventional procedures, longer ICU and hospital stays, hospital re-admissions, and sometimes even death due to the complications caused by inadequate drainage.”

The company is currently raising capital for further clinical expansion to serve heart surgery patients worldwide, as well as to build its pipeline of products for other surgical fields. The PleuraFlow System with Active Clearance Technology is approved for use in the United States, Europe, Australia, Brazil and Canada, and has either cleared or pending clearance in nearly a dozen additional countries.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init